Ex-Takeda exec Tadataka Yamada rejoins Frazier Healthcare
This article was originally published in Scrip
Executive Summary
Frazier Healthcare, a provider of growth capital to healthcare companies, has announced Dr Tadataka Yamada will rejoin the firm. He will serve as a venture partner on the life sciences team, focused on creating new companies as well as providing strategic guidance to existing portfolio companies. He will also be a senior advisor to the growth buyout team, where he will provide advice on opportunities in pharmaceutical services and spin-outs from large healthcare companies, and sit on boards of portfolio companies such as PCI, a large pharmaceutical services company in the Frazier portfolio. Before rejoining Frazier, Dr Yamada was chief medical and scientific officer at Takeda Pharmaceuticals in Tokyo, as well as a member of the company's board of directors. Previously he was chair of R&D at GlaxoSmithKline and a member of the company's board.